Nextcure presents preclinical data on a novel therapeutic candidate targeting vstm-1 for the treatment of progressive inflammatory airway disorders

Beltsville, md., jan. 18, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting vstm-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease (copd), at the keystone symposium for inhibitory receptors in immune homeostasis, disease and therapy.
NXTC Ratings Summary
NXTC Quant Ranking